Market segments covered by this report include tissue engineering and cell transplantation products for bladder repair and replacement, incontinence treatment, penile replacement and prostheses, and urethral augmentation. A variety of tissue engineering approaches show promise for treating diseases and disorders of the urogenital system including cell-based gene therapy, growth factors, injectable scaffolds, stem cell therapy, and tissue-engineered bladders, ureters, and ureteral segments.
The clinical overview section of this report provides a synopsis of selected urogenital diseases and disorders including up-to-date incidence and prevalence numbers for each.
This report is the fourth in a series of six Medtech Insight reports covering U.S. tissue engineering markets. Upcoming reports in this series will provide analyses of U.S. markets for tissue-engineered organ regeneration and skin replacement products.
EXECUTIVE SUMMARY i. Selected Urogenital Diseases and Disorders a. Bladder Cancer b. Erectile Dysfunction c. Prostate Cancer d. Urinary Incontinence ii. Existing Therapies a. Bladder, Ureteral, and Urethral Repair b. Incontinence Treatment c. Penile Prostheses d. Vesicoureteral Reflux Treatment iii. Tissue Engineering Technologies a. Biomaterials b. Cell Culture Technology c. Stem Cell Technology d. Immunoisolation Technology iv. U.S. Markets for Urogenital Tissue Engineering and Cell Transplantation Products a. Bladder Repair and Replacement b. Gene Therapy c. Reconstituted Structures d. Ureteral and Urethral Repair and Replacement e. Urethral Augmentation f. Market Analysis v. Methodology Exhibit ES-1: Tissue Engineering and Cell Transplantation Products for Urogenital Applications, Potential Market Forecast, 2009 and 2019 1. OVERVIEW OF SELECTED UROGENITAL DISEASES AND DISORDERS 1.1 Selected Urogenital Diseases and Disorders 1.1.1 Bladder Cancer 1.1.2 Erectile Dysfunction 1.1.3 Prostate Cancer 1.1.4 Urinary Incontinence 1.2 Existing Therapies 1.2.1 Bladder, Ureteral, and Urethral Repair 1.2.2 Incontinence Treatment 1.2.3 Penile Prostheses 1.2.4 Vesicoureteral Reflux Treatment Exhibit 1-1: 2009, Incidence and Prevalence of Urogenital Diseases and Disorders Potentially Treatable Using Tissue Engineering Exhibit 1-2: Bladder Cancer, Facts and Figures Exhibit 1-3: Erectile Dysfunction, Facts and Figures Exhibit 1-4: Prostate Cancer, Facts and Figures Exhibit 1-5: Urinary Incontinence, Facts and Figures Exhibit 1-6: Types of Urinary Incontinence Exhibit 1-7: 2009, Urogenital Treatments, Procedure Volumes 2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES 2.1 Biomaterials 2.1.1 Synthetic Biomaterials 2.1.2 Biologically Derived Biomaterials 220.127.116.11 Collagen 18.104.22.168 Xenogeneic Tissue 2.1.3 Hybrid Biomaterials 2.1.4 Genetically Engineered Biomaterials 22.214.171.124 Deoxyribonucleic Acid Transfection Vectors 126.96.36.199 Genetically Manipulated Cells 188.8.131.52 Three-Dimensional Polymer Technology 184.108.40.206 Transgenics 220.127.116.11 Fibroblasts 18.104.22.168 Immortalized Neural Stem Cells 22.214.171.124 Gene-Activated Matrices 2.1.5 Scaffolds 2.1.6 Vascular Grafts 2.2 Cell Culture Technology 2.2.1 Bioreactors 126.96.36.199 Flatbed Perfusion Systems 188.8.131.52 Hollow Fiber Bioreactor Systems 184.108.40.206 Cell Suspension Systems 220.127.116.11 Disposable Bioreactors 2.3 Stem Cell Technology 2.3.1 Cell Extraction and Expansion 2.3.2 Bioreactors 2.4 Immunoisolation Technology 2.4.1 Chimeric Immunity 2.4.2 Cell Encapsulation Technology Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies 3. U.S. MARKETS FOR UROGENITAL TISSUE ENGINEERING AND CELL TRANSPLANTATION PRODUCTS 3.1 Biomaterials 3.2 Bladder Repair and Replacement 3.2.1 Tengion 3.3 Gene Therapy Products 3.3.1 Ion Channel Innovations 3.4 Reconstituted Structures 3.5 Ureteral and Urethral Repair and Replacement Products 3.5.1 C.R. Bard 3.5.2 Boston Scientific 3.5.3 Cook Biotech/Cook Group 3.5.4 Innovacell Biotechnologie 3.5.5 Tengion 3.6 Urethral Augmentation Products 3.6.1 C.R. Bard 3.6.2 Boston Scientific 3.6.3 Oceana Therapeutics 3.6.4 Uroplasty 3.7 Market Analysis 3.7.1 Market Drivers 3.7.2 Market Limiters 3.8 Competitive Analysis Exhibit 3-1: 2010, Selected Tissue Engineering and Cell Transplantation Products for Urogenital Applications Exhibit 3-2: Tissue Engineering and Cell Transplantation Products for Urogenital Applications, Potential Market Forecast, 2009 and 2019 Exhibit 3-3: Tissue Engineering and Cell Transplantation Technologies for Urogenital Applications, by Indication, 2009 and 2019 Exhibit 3-4: Tissue Engineering and Cell Transplantation Products for Urogenital Applications, Product Introduction Forecast, 2014 and 2019 4. COMPANY PROFILES 4.1 C.R. Bard, Inc. 4.2 Boston Scientific Corporation 4.3 Cook Group, Inc. 4.4 Innovacell Biotechnologie AG 4.5 Ion Channel Innovations LLC 4.6 LifeCell Corporation/Kinetic Concepts, Inc. 4.7 Merz Pharmaceuticals, Inc. 4.8 Q-Med AB 4.9 TEI Biosciences, Inc. 4.10 Tengion, Inc. 4.11 Uroplasty, Inc. APPENDIX: COMPANY LISTING